Location of Repository

Basal Breast Cancer: A Complex and Deadly Molecular Subtype

By F Bertucci, P Finetti and D Birnbaum

Abstract

During the last decade, gene expression profiling of breast cancer has revealed the existence of five molecular subtypes and allowed the establishment of a new classification. The basal subtype, which represents 15-25% of cases, is characterized by an expression profile similar to that of myoepithelial normal mammary cells. Basal tumors are frequently assimilated to triple-negative (TN) breast cancers. They display epidemiological and clinico-pathological features distinct from other subtypes. Their pattern of relapse is characterized by frequent and early relapses and visceral locations. Despite a relative sensitivity to chemotherapy, the prognosis is poor. Recent characterization of their molecular features, such as the dysfunction of the BRCA1 pathway or the frequent expression of EGFR, provides opportunities for optimizing the systemic treatment. Several clinical trials dedicated to basal or TN tumors are testing cytotoxic agents and/or molecularly targeted therapies. This review summarizes the current state of knowledge of this aggressive and hard-to-treat subtype of breast cancer

Topics: Article
Publisher: Bentham Science Publishers
OAI identifier: oai:pubmedcentral.nih.gov:3343384
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles

    Preview

    Citations

    1. (2005). A basal epithelial phenotype is more frequent in interval breast cancers compared with screen detected tumors. Cancer Epidemiol Biomarkers Prev
    2. (2011). A gene expression signature identifies two prognostic subgroups of basal breast cancer. Breast Cancer Res Treat
    3. (2007). A gene signature in breast cancer.
    4. (2002). A geneexpression signature as a predictor of survival in breast cancer.
    5. (2004). A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.
    6. (2012). A phase II trial of the PARP inhibitor veliparib (ABT888) and temozolomide for 110 Current Molecular Medicine,
    7. A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC). J Clin Oncol 2011; 29: (suppl; abstr 1007).
    8. (2008). A robust classifier of high predictive value to identify good prognosis patients in ERnegative breast cancer. Breast Cancer Res
    9. (2009). Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat Med
    10. (1998). Aberrant methylation of the BRCA1 CpG island promoter is associated with decreased BRCA1 mRNA in sporadic breast cancer cells. Oncogene
    11. (2007). Abrogated response to cellular stress identifies DCIS associated with subsequent tumor events and defines basal-like breast tumors. Cancer Cell
    12. (2006). AlphaB-crystallin is a novel oncoprotein that predicts poor clinical outcome in breast cancer.
    13. (2005). An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival.
    14. (2007). An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. Genome Biol
    15. (2007). an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro. Breast Cancer Res Treat
    16. (2008). Analysis of integrin beta4 expression in human breast cancer: association with basal-like tumors and prognostic significance. Clin Cancer Res
    17. (2008). are associated with breast cancer basal-like and triple-negative immunophenotype.
    18. (2010). BARD1 homozygous deletion, a possible alternative to BRCA1 mutation in basal breast cancer. Genes Chromosomes Canc
    19. (2004). Basal and luminal breast cancers: basic or luminous?
    20. (2008). Basal breast cancer molecular subtype predicts for lower incidence of axillary lymph node metastases in primary breast cancer. Clin Breast Cancer
    21. (2005). Basal cytokeratins and their relationship to the cellular origin and functional classification of breast cancer. Breast Cancer Res
    22. (2006). Basal phenotype identifies a poor prognostic subgroup of breast cancer of clinical importance.
    23. (2006). Basal phenotype of ductal carcinoma in situ: recognition and immunohistologic profile. Mod Pathol
    24. (2008). Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res
    25. (2008). Basal-like breast cancer: a critical review.
    26. (2006). Basal-like breast carcinomas: clinical outcome and response to chemotherapy.
    27. (2007). Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival. Breast Cancer Res
    28. (2007). Basal-like phenotype is not associated with patient survival in estrogen-receptor-negative breast cancers. Breast Cancer Res
    29. (2008). Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res
    30. (2010). BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells. Cell Stem Cell
    31. (2007). BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene
    32. (2004). BRCA1 functions as a breast stem cell regulator.
    33. (2003). BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Res
    34. (1999). BRCA1 inhibition of estrogen receptor signaling in transfected cells. Science
    35. (2005). BRCA1 promoter methylation in sporadic breast tumors: relationship to gene expression profiles. Breast Cancer Res Treat
    36. (2008). BRCA1 regulates human mammary stem/progenitor cell fate.
    37. (2003). Breast cancer classification and prognosis based on gene expression profiles from a population-based study.
    38. (2010). Breast cancer molecular profiling with single sample predictors: a retrospective analysis. Lancet Oncol
    39. (2007). Breast cancer molecular subclassification and estrogen receptor expression to predict efficacy of adjuvant anthracyclines-based chemotherapy: a biomarker study from two randomized trials. Ann Oncol
    40. (2005). Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res
    41. (2008). Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy.
    42. (2009). Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial.
    43. (2006). breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA
    44. (2004). Breast cancer, stem/progenitor cells and the estrogen receptor. Trends Endocrinol Metab
    45. (2006). Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR.
    46. (2011). Breast carcinomas arising at a young age: unique biology or a surrogate for aggressive intrinsic subtypes?
    47. (2008). Cancer stem cells in breast: current opinion and future challenges. Pathobiology
    48. (2000). central acellular zones indicating myoepithelial tumor differentiation in high-grade invasive ductal carcinomas as markers of predisposition to lung and brain metastases.
    49. (2008). Cerebral metastases (CM) in breast cancer (BC) with focus on triple-negative tumors.
    50. (2009). Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res
    51. (2006). Classification and risk stratification of invasive breast carcinomas using a realtime quantitative RT-PCR assay. Breast Cancer Res
    52. (2006). Classification of ductal carcinoma in situ by gene expression profiling. Breast Cancer Res
    53. (2009). Clinical significance of basal-like subtype in triple-negative breast cancer. Breast Cancer
    54. (2006). Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes. Hum Pathol
    55. (2007). Common variants on chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptor-positive breast cancer. Nat Genet
    56. (2006). Concordance among geneexpression-based predictors for breast cancer.
    57. (2004). Conservation of breast cancer molecular subtypes and transcriptional patterns of tumor progression across distinct ethnic populations. Clin Cancer Res
    58. (2010). Current treatment options in triple negative breast cancer. Breast Dis
    59. (2002). Cytogenetic alterations and cytokeratin expression patterns in breast cancer: integrating a new model of breast differentiation into cytogenetic pathways of breast carcinogenesis. Lab Invest
    60. (2005). Depletion of BRCA1 impairs differentiation but enhances proliferation of mammary epithelial cells.
    61. (2007). Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer
    62. (2007). Differences in breast carcinoma characteristics in newly diagnosed AfricanAmerican and Caucasian patients: a single-institution compilation compared with the National Cancer Institute's Surveillance, Epidemiology, and End Results database. Cancer
    63. (2007). Differences in risk factors for breast cancer molecular subtypes in a populationbased study. Cancer Epidemiol Biomarkers Prev
    64. (2010). Directed therapy of subtypes of triple-negative breast cancer. Oncologist
    65. (2006). Discovery and validation of breast cancer subtypes.
    66. (2008). Distant disease-free interval, site of first relapse and post-relapse survival in BRCA1- and BRCA2-associated compared to sporadic breast cancer patients. Breast Cancer Res Treat
    67. (2006). Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms.
    68. (2006). Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer. Genes Chromosomes Cancer
    69. (2009). Do 'basal-like' breast cancers really exist? Nat Rev Cancer
    70. (2006). Ductal carcinoma in situ with basal-like phenotype: a possible precursor to invasive basal-like breast cancer. Mod Pathol
    71. (2010). Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study. Breast Cancer Res Treat
    72. (2006). Efficacy of high-dose alkylating chemotherapy in HER2/neu-negative breast cancer. Ann Oncol
    73. (2010). Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer.
    74. (2008). Epidemiology of basal-like breast cancer. Breast Cancer Res Treat
    75. (2008). Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group.
    76. (2010). Expanding the criteria for BRCA mutation testing in breast cancer survivors.
    77. (2002). Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome.
    78. (2009). Expression of epidermal growth factor receptor in relation to BRCA1 status, basal-like markers and prognosis in breast cancer.
    79. (2007). F a lo C , Mo re no A , V a re la M, et al. HER-2/neu status and response to CMF: retrospective study in a series of operable breast cancer treated with primary CMF chemotherapy.
    80. (2001). Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications.
    81. (2006). Gene expression profiling and clinical outcome in breast cancer. Omics
    82. (2007). Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res
    83. (2005). Gene expression profiling identifies molecular subtypes of inflammatory breast cancer. Cancer Res
    84. (2006). Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis.
    85. (2006). Gene expression profiling of breast cell lines identifies potential new basal markers. Oncogene
    86. (2001). Gene expression profiling of cancer by use of DNA arrays: how far from the clinic? Lancet Oncol
    87. (2002). Gene expression profiling predicts clinical outcome of breast cancer.
    88. (2006). Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers. Cancer Res
    89. (2004). Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. PLoS Biol
    90. (2005). Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet
    91. (2008). Genetic susceptibility loci for breast cancer by estrogen receptor status. Clin Cancer Res
    92. (2007). Genome-wide association study identifies novel breast cancer susceptibility loci. Nature
    93. (2006). Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell
    94. (2003). Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer.
    95. (2007). HER2 and response to paclitaxel in node-positive breast cancer.
    96. (2008). Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics. PLoS Genet
    97. (2007). High-resolution aCGH and expression profiling identifies a novel genomic subtype of ER negative breast cancer. Genome Biol
    98. (2001). Homology-directed DNA repair, mitomycin-c resistance, and chromosome stability is restored with correction of a Brca1 mutation. Cancer Res
    99. (2008). How basal are triplenegative breast cancers?
    100. (2009). How different are luminal A and basal breast cancers?
    101. (2007). Identification of a basal-like subtype of breast ductal carcinoma in situ. Hum Pathol
    102. (2007). Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection. Cancer Res
    103. (2006). Identification of cell-of-origin breast tumor subtypes in inflammatory breast cancer by gene expression profiling. Breast Cancer Res Treat
    104. (2011). Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.
    105. (2009). Identification of novel kinase targets for the treatment of estrogen receptornegative breast cancer. Clin Cancer Res
    106. (2004). Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res
    107. (2011). Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neoadjuvant chemotherapy trials. Breast Cancer Res Treat
    108. (2009). In vitro and in vivo analysis of B-Myb in basal-like breast cancer. Oncogene
    109. (2011). Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res
    110. (2011). Iniparib plus chemotherapy in metastatic triple-negative breast cancer.
    111. (2007). Integrated profiling of basal and luminal breast cancers. Cancer Res
    112. (2010). Interactions with fibroblasts are distinct in Basal-like and luminal breast cancers. Mol Cancer Res
    113. (2010). Intrinsic breast tumor subtypes, race, and long-term survival in the Carolina Breast Cancer Study. Clin Cancer Res
    114. (2006). Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients. Breast Cancer Res
    115. (2011). Kinome expression profiling and prognosis of basal breast cancers. Mol Cancer
    116. (2006). Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer.
    117. (2004). Loss of heterozygosity and its correlation with expression profiles in subclasses of invasive breast cancers. Cancer Res
    118. (2007). Moesin expression is a marker of basal breast carcinomas.
    119. (2009). Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array. Clin Cancer Res
    120. (2007). Molecular classification system identifies invasive breast carcinoma patients who are most likely and those who are least likely to achieve a complete pathologic response after neoadjuvant chemotherapy. Cancer
    121. (2000). Molecular portraits of human breast tumours. Nature
    122. (2010). Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer. Breast Cancer Res Treat
    123. (2010). Molecular stratification of triple-negative breast cancers. Oncologist
    124. (2006). Molecular subtypes of breast cancer and amplification of topoisomerase II alpha: predictive role in dose intensive adjuvant chemotherapy.
    125. (2006). Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation.
    126. (2009). Neoadjuvant cisplatin and bevacizumab in triple negative breast cancer (TNBC): Safety and efficacy.
    127. (2010). Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-ofconcept trial. Lancet
    128. (2007). Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol
    129. (2007). P-cadherin and cytokeratin 5: useful adjunct markers to distinguish basal-like ductal carcinomas in situ. Virchows Arch
    130. (2007). Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.
    131. (2010). Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy.
    132. (2011). Peritumoural vascular invasion: a major determinant of triple-negative breast cancer outcome.
    133. (2006). Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer.
    134. (2008). Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.
    135. Phase II trial of dasatinib in triple-negative breast cancer: results of study CA. Cancer Res 2009; 69: Abstract no.
    136. (2010). Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res
    137. (2005). Placental cadherin and the basal epithelial phenotype of BRCA1-related breast cancer. Clin Cancer Res
    138. (2011). Poly(ADP-ribose) polymerase-1 mRNA expression in human breast cancer: a meta-analysis. Breast Cancer Res Treat
    139. (2007). Poor prognosis in breast carcinomas correlates with increased expression of targetable CD146 and c-Met and with proteomic basal-like phenotype. Hum Pathol
    140. (2009). Population differences in breast cancer: survey in indigenous African Women Reveals over-representation of triple-negative breast cancer.
    141. (2005). Population-based validation of the prognostic model ADJUVANT! for early breast cancer.
    142. (2009). Prediction of local recurrence, distant metastases, and death after breastconserving therapy in early-stage invasive breast cancer using a five-biomarker panel.
    143. (2007). Preliminary results of a randomized phase II study of weekly irinotecan/carboplatin with or without cetuximab in patients with metastatic breast cancer. 30th Annual San Antonio Breast Cancer Symposium,
    144. (2009). Preliminary safety and activity results of trabectedin in a phase II trial dedicated to triple-negative (ER-, PR-, HER2-), HER2+++, or BRCA1/2 germ-line-mutated metastatic breast cancer (MBC) patients (pts).
    145. (2005). Prognostic relevance of basal cytokeratin expression in operable breast cancer. Oncology
    146. (2006). Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas. Clin Cancer Res
    147. (2007). Protein expression profiling in high-risk breast cancer patients treated with highdose or conventional dose-dense chemotherapy. Clin Cancer Res
    148. (2006). Purification and unique properties of mammary epithelial stem cells. Nature
    149. (2006). Relationship between nuclear grade of ductal carcinoma in situ and cell origin markers. Ann Clin Lab Sci
    150. (2003). Repeated observation of breast tumor subtypes in independent gene expression data sets.
    151. (2009). Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features.
    152. (2008). Resistance to therapy caused by intragenic deletion in BRCA2. Nature
    153. (2008). Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer.
    154. (2009). Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res Treat
    155. (2006). Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast. Histopathology
    156. (2008). Subtypes of breast cancer show preferential site of relapse. Cancer Res
    157. (2009). Supervised risk predictor of breast cancer based on intrinsic subtypes.
    158. (2009). T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers. Breast Cancer Res
    159. (2007). Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care? Nat Rev Cancer
    160. (2005). Targeting the DNA repair defect of BRCA tumours. Curr Opin Pharmacol
    161. (2008). TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer.
    162. (2000). The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin.
    163. (2008). The functional loss of the retinoblastoma tumour suppressor is a common event in basal-like and luminal B breast carcinomas. Breast Cancer Res
    164. (2008). The influence of basal phenotype on the metastatic pattern of breast cancer.
    165. (2006). The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics
    166. (2005). The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell
    167. (2007). The phenotypic spectrum of basallike breast cancers: a critical appraisal. Adv Anat Pathol
    168. (2004). The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/ glomeruloid-microvascular-proliferation+) phenotype of BRCA1-related breast cancer. Cancer Res
    169. (2007). The prognostic role of a gene signature from tumorigenic breast-cancer cells.
    170. (2004). The role of BRCA1 in the cellular response to chemotherapy.
    171. (2007). The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res
    172. (2009). Time to disease recurrence in basal-type breast cancers: effects of tumor size and lymph node status. Cancer
    173. (2007). TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer. Breast Cancer Res
    174. (2007). Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res
    175. (2007). Triple-negative breast cancer: therapeutic options. Lancet Oncol
    176. (2009). Triple-negative breast cancers are increased in black women regardless of age or body mass index. Breast Cancer Res
    177. (2008). Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial. Ann Oncol
    178. (2009). Triple-negative/basal-like breast cancer: review. Pathology
    179. (2005). Typical medullary breast carcinomas have a basal/myoepithelial phenotype.
    180. (2006). X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.